Celecoxib and radioresistant glioblastoma-derived CD133+ cells: Improvement in radiotherapeutic effects. Laboratory investigation

Journal of Neurosurgery

Volumn 114, Issue 3, 2011, Pages 651-662

  Ma, Hsin I ^a   Chiou, Shih Hwa ^b,c   Hueng, Dueng Yuan ^a   Tai, Lung Kuo ^b,c   Huang, Pin I ^b,c   Kao, Chung Lan ^b,c   Chen, Yi Wei ^b,c   Sytwu, Huey Kang ^a  

^a TRI SERVICE GENERAL HOSPITAL   (Taiwan)

^b TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^c NATIONAL YANG MING UNIVERSITY   (Taiwan)

Author keywords

CD133; cdc2; Celecoxib; Glioma stemlike cells; Radioresistance

Indexed keywords

CD133 ANTIGEN; CELECOXIB; COBALT; CYCLIN B; CYCLIN DEPENDENT KINASE 1; CYCLOOXYGENASE 2; MESSENGER RNA; RADIOSENSITIZING AGENT;

ADULT; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER ADJUVANT THERAPY; CANCER GROWTH; CANCER INHIBITION; CANCER INVASION; CANCER RADIOTHERAPY; CANCER RESEARCH; CANCER SURVIVAL; CARCINOGENICITY; CELL CYCLE; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CLONOGENIC ASSAY; COBALT THERAPY; COLONY FORMATION; CONTROLLED STUDY; CORPUS STRIATUM; DRUG MECHANISM; ENZYME PHOSPHORYLATION; FEMALE; FLOW CYTOMETRY; GLIOBLASTOMA; GLIOMA CELL; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; IONIZING RADIATION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RADIOSENSITIVITY; SCID MOUSE; WESTERN BLOTTING; XENOTRANSPLANTATION;

AGED; ANIMALS; ANTIGENS, CD; ANTINEOPLASTIC AGENTS; APOPTOSIS; BLOTTING, WESTERN; BRAIN NEOPLASMS; CELL DIVISION; CELL LINE, TUMOR; CELL SEPARATION; CULTURE MEDIA; CYCLOOXYGENASE 2; DRUG RESISTANCE, NEOPLASM; FLOW CYTOMETRY; FLUORESCENT ANTIBODY TECHNIQUE; G2 PHASE; GLIOBLASTOMA; GLYCOPROTEINS; HUMANS; IN SITU NICK-END LABELING; MALE; MICE; MICE, SCID; MIDDLE AGED; NEOPLASTIC STEM CELLS; PEPTIDES; PYRAZOLES; SULFONAMIDES; SURVIVAL ANALYSIS; UP-REGULATION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 79952275286     PISSN: 00223085     EISSN: 19330693     Source Type: Journal    
DOI: 10.3171/2009.11.JNS091396     Document Type: Article

References (44)

1. Altaner C: Glioblastoma and stem cells. Neoplasma 55:369-374, 2008
2. Antonarakis ES, Heath EI, Walczak JR, Nelson WG, Fedor H, De Marzo AM, et al: Phase II, randomized, placebo-controlled trial of neoadjuvant celecoxib in men with clinically localized prostate cancer: evaluation of drug-specific biomarkers. J Clin Oncol 27:4986-4993, 2009
3. Bao S, Wu Q, McLendon RE, Hao Y, Shi Q, Hjelmeland AB, et al: Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 444: 756-760, 2006 (Pubitemid 44949604)
4. Beier D, Wischhusen J, Dietmaier W, Hau P, Proescholdt M, Brawanski A, et al: CD133 expression and cancer stem cells predict prognosis in high-grade oligodendroglial tumors. Brain Pathol 18:370-377, 2008 (Pubitemid 351782845)
5. Chang CJ, Hsu CC, Yung MC, Chen KY, Tzao C, Wu WF, et al: Enhanced radiosensitivity and radiation-induced apoptosis in glioma CD133-positive cells by knockdown of SirT1 expression. Biochem Biophys Res Commun 380:236-242, 2009
6. Chen JC, Chen Y, Su YH, Tseng SH: Celecoxib increased ex pression of 14-3-3sigma and induced apoptosis of glioma cells. Anticancer Res 27 (4B):2547-2554, 2007 (Pubitemid 47232274)
7. Chiou SH, Kao CL, Chen YW, Chien CS, Hung SC, Lo JF, et al: Identification of CD133-positive radioresistant cells in atypical teratoid/rhabdoid tumor. PLoS One 3:e2090, 2008
8. Chiou SH, Kao CL, Lin HT, Tseng WS, Liu RS, Chung CF, et al: Monitoring the growth effect of xenotransplanted human medulloblastoma in an immunocompromised mouse model using in vitro and ex vivo green fluorescent protein imaging. Childs Nerv Syst 22:475-480, 2006
9. Clement V, Sanchez P, de Tribolet N, Radovanovic I, Ruiz i Altaba A: HEDGEHOG-GLI1 signaling regulates human glioma growth, cancer stem cell self-renewal, and tumorigenicity. Curr Biol 17:165-172, 2007 (Pubitemid 46107823)
10. Debucquoy A, Roels S, Goethals L, Libbrecht L, Van Cutsem E, Geboes K, et al: Double blind randomized phase II study with radiation+5- fluorouracil±celecoxib for resectable rectal cancer. Radiother Oncol 93:273-278, 2009
11. Dehdashti AR, Hegi ME, Regli L, Pica A, Stupp R: New trends in the medical management of glioblastoma multiforme: the role of temozolomide chemotherapy. Neurosurg Fo cus 20(4):E6, 2006
12. Furuta Y, Hall ER, Sanduja S, Barkley T Jr, Milas L: Prostaglandin production by murine tumors as a predictor for therapeutic response to indomethacin. Cancer Res 48:3002-3007, 1988
13. Furuta Y, Hunter N, Barkley T Jr, Hall E, Milas L: Increase in radioresponse of murine tumors by treatment with indomethacin. Cancer Res 48:3008-3013, 1988
14. Galli R, Binda E, Orfanelli U, Cipelletti B, Gritti A, De Vitis S, et al: Isolation and characterization of tumorigenic, stemlike neural precursors from human glioblastoma. Cancer Res 64:7011-7021, 2004 (Pubitemid 39331011)
15. Gasparini G, Longo R, Sarmiento R, Morabito A: Inhibitors of cyclo-oxygenase 2: a new class of anticancer agents? Lancet Oncol 4:605-615, 2003 (Pubitemid 37258402)
16. Grösch S, Maier TJ, Schiffmann S, Geisslinger G: Cyclooxygenase- 2 (COX-2)-independent anticarcinogenic effects of selective COX-2 inhibitors. J Natl Cancer Inst 98:736-747, 2006 (Pubitemid 43983297)
17. Hide T, Takezaki T, Nakamura H, Kuratsu J, Kondo T: Brain tumor stem cells as research and treatment targets. Brain Tumor Pathol 25:67-72, 2008
18. Kang KB, Wang TT, Woon CT, Cheah ES, Moore XL, Zhu C, et al: Enhancement of glioblastoma radioresponse by a selective COX-2 inhibitor celecoxib: inhibition of tumor angiogenesis with extensive tumor necrosis. Int J Radiat Oncol Biol Phys 67:888-896, 2007 (Pubitemid 46215892)
19. Kao CL, Huang PI, Tsai PH, Tsai ML, Lo JF, Lee YY, et al: Resveratrol-induced apoptosis and increased radiosensitivity in CD133-positive cells derived from atypical teratoid/rhabdoid tumor. Int J Radiat Oncol Biol Phys 74:219-228, 2009
20. Kawabe T: G2 checkpoint abrogators as anticancer drugs. Mol Cancer Ther 3:513-519, 2004
21. Kesari S, Schiff D, Henson JW, Muzikansky A, Gigas DC, Doherty L, et al: Phase II study of temozolomide, thalidomide, and celecoxib for newly diagnosed glioblastoma in adults. Neuro Oncol 10:300-308, 2008
22. Knizetova P, Darling JL, Bartek J: Vascular endothelial growth factor in astroglioma stem cell biology and response to therapy. J Cell Mol Med 12:111-125, 2008
23. Kuipers GK, Slotman BJ, Wedekind LE, Stoter TR, Berg J, Sminia P, et al: Radiosensitization of human glioma cells by cyclooxygenase-2 (COX-2) inhibition: independent on COX- 2 expression and dependent on the COX-2 inhibitor and sequence of administration. Int J Radiat Biol 83:677-685, 2007 (Pubitemid 47345866)
24. Liao Z, Komaki R, Milas L, Yuan C, Kies M, Chang JY, et al: A phase I clinical trial of thoracic radiotherapy and concurrent celecoxib for patients with unfavorable performance status inoperable/unresectable non-small cell lung cancer. Clin Cancer Res 11:3342-3348, 2005 (Pubitemid 40627885)
25. Lin CP, Tseng WY, Cheng HC, Chen JH: Validation of diffusion tensor magnetic resonance axonal fiber imaging with registered manganese-enhanced optic tracts. Neuroimage 14: 1035-1047, 2001
26. Liu W, Chen Y, Wang W, Keng P, Finkelstein J, Hu D, et al: Combination of radiation and celebrex (celecoxib) reduce mammary and lung tumor growth. Am J Clin Oncol 26: S103-S109, 2003 (Pubitemid 36961150)
27. Ma S, Chan KW, Hu L, Lee TK, Wo JY, Ng IO, et al: Identification and characterization of tumorigenic liver cancer stem/ progenitor cells. Gastroenterology 132:2542-2556, 2007 (Pubitemid 46890873)
28. Mantovani G, Macciò A, Madeddu C, Serpe R, Antoni G, Massa E, et al: Phase II nonrandomized study of the efficacy and safety of COX-2 inhibitor celecoxib on patients with cancer cachexia. J Mol Med 88:85-92, 2010
29. McAdam BF, Catella-Lawson F, Mardini IA, Kapoor S, Lawson JA, FitzGerald GA: Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: the human pharmacology of a selective inhibitor of COX-2. Proc Natl Acad Sci U S A 96: 272-277, 1999 (Pubitemid 29036089)
30. Miki J, Furusato B, Li H, Gu Y, Takahashi H, Egawa S, et al: Identification of putative stem cell markers, CD133 and CXCR4, in hTERT-immortalized primary nonmalignant and malignant tumor-derived human prostate epithelial cell lines and in prostate cancer specimens. Cancer Res 67:3153-3161, 2007 (Pubitemid 46724852)
31. Mizrak D, Brittan M, Alison MR: CD133: molecule of the moment. J Pathol 214:3-9, 2008
32. Mutter R, Lu B, Carbone DP, Csiki I, Moretti L, Johnson DH, et al: A phase II study of celecoxib in combination with paclitaxel, carboplatin, and radiotherapy for patients with inoperable stage IIIA/B non-small cell lung cancer. Clin Cancer Res 15:2158-2165, 2009
33. Nakata E, Mason KA, Hunter N, Husain A, Raju U, Liao Z, et al: Potentiation of tumor response to radiation or chemoradiation by selective cyclooxygenase-2 enzyme inhibitors. Int J Radiat Oncol Biol Phys 58:369-375, 2004 (Pubitemid 38142461)
34. Nurse P: Universal control mechanism regulating onset of Mphase. Nature 344:503-508, 1990
35. Pawlik TM, Keyomarsi K: Role of cell cycle in mediating sensitivity to radiotherapy. Int J Radiat Oncol Biol Phys 59: 928-942, 2004 (Pubitemid 38834285)
36. Ricci-Vitiani L, Lombardi DG, Pilozzi E, Biffoni M, Todaro M, Peschle C, et al: Identification and expansion of human colon-cancer-initiating cells. Nature 445:111-115, 2007 (Pubitemid 46067311)
37. Sheng H, Shao J, Kirkland SC, Isakson P, Coffey RJ, Morrow J, et al: Inhibition of human colon cancer cell growth by selective inhibition of cyclooxygenase-2. J Clin Invest 99:2254-2259, 1997 (Pubitemid 27203783)
38. Singh SK, Hawkins C, Clarke ID, Squire JA, Bayani J, Hide T, et al: Identification of human brain tumour initiating cells. Na ture 432:396-401, 2004 (Pubitemid 39551674)
39. Smits VA, Medema RH: Checking out the G(2)/M transition. Biochim Biophys Acta 1519:1-12, 2001
40. Stupp R, Hegi ME, Gilbert MR, Chakravarti A: Chemoradiotherapy in malignant glioma: standard of care and future directions. J Clin Oncol 25:4127-4136, 2007 (Pubitemid 47492957)
41. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, et al : Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987-996, 2005 (Pubitemid 40349501)
42. Tang C, Chua CL, Ang BT: Insights into the cancer stem cell model of glioma tumorigenesis. Ann Acad Med Singapore 36:352-357, 2007 (Pubitemid 47121450)
43. Zeppernick F, Ahmadi R, Campos B, Dictus C, Helmke BM, Becker N, et al: Stem cell marker CD133 affects clinical outcome in glioma patients. Clin Cancer Res 14:123-129, 2008 (Pubitemid 351377986)
44. Zhu L, Gibson P, Currle DS, Tong Y, Richardson RJ, Bayazitov IT, et al: Prominin 1 marks intestinal stem cells that are susceptible to neoplastic transformation. Nature 457:603-607, 2009